– ARCALYST ® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – ...
Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their ...
CEO Sanj Patel highlighted that Kiniksa achieved $137.8 million in net product revenue for ARCALYST during Q1 2025, marking a 75% increase year-over-year. This success was attributed to robust ...
Image source: The Motley Fool. Kiniksa Pharmaceuticals (NASDAQ:KNSA) highlighted rapid ARCALYST revenue expansion and expanding treatment adoption across its addressable pericarditis market. The ...
Hosted on MSN
Kiniksa outlines $900M–$920M 2026 ARCALYST revenue guidance as market penetration deepens
Earnings Call Insights: Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Sanj Patel, CEO, stated that "ARCALYST revenue continues to grow, driven by the expanding adoption of IL-1 alpha and ...
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
Kiniksa is recruiting patients in the dose-focusing portion of the Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis. The company expects data from this portion of the trial in the second ...
– ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively – – ARCALYST 2024 net product revenue expected to be $360 - $380 million, ...
Kiniksa Pharmaceuticals is set to begin a Phase 2/3 clinical trial for its drug KPL-387, aimed at treating recurrent pericarditis, in mid-2025. The company has noted that data from the ongoing Phase 1 ...
"ARCALYST Sales Forecast"Kiniksa Pharmaceuticals has recently reported strong year-over-year revenue growth for ARCALYST, driven primarily by its expanding use in recurrent pericarditis. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results